TRexBio Announces a First Option Was Exercised by Partner
TRexBio Announces Development Candidate, TRB-061
Johnston Erwin has persuaded some old friends to up their bet on TRexBio. Twenty months after taking over as CEO of the biotech, the Eli Lilly veteran has landed a deal with his former employer that sees the trade of $55 million for exclusive rights to three regulatory T-cell (Treg) programs.
Market Place
Share
Share
